Canine Heartworm Disease: Transmission, Prevention, and Treatment

Etiology and Life Cycle

Canine heartworm disease is a mosquito-borne filarial infection caused by the nematode Dirofilaria immitis [1, 2]. The adult parasites reside within the pulmonary arteries and right ventricle of the heart, causing progressive vascular and parenchymal damage [3, 4]. The life cycle involves an obligate intermediate host, mosquitoes of the genera Culex, Aedes, and Anopheles [5, 6]. Microfilariae (L1 larvae) circulate in the peripheral blood of an infected canid and are ingested by a feeding mosquito [1]. Within the insect, larvae develop through two molts (L1 to L2, L2 to L3) over a temperature-dependent extrinsic incubation period (EIP) [7, 8]. The EIP requires a cumulative thermal input, quantified as heartworm development units (HDUs), and is completed only when ambient temperatures are consistently above a threshold of approximately 14°C [7, 8]. This temperature-bounded development restricts the geographical distribution and seasonality of transmission [7, 8]. Infective L3 larvae are deposited onto the skin during subsequent mosquito blood meals, enter the host through the puncture wound, and molt to L4 and then L5 (immature adult) within the subcutaneous tissues and muscle [1, 2]. Immature adults migrate to the pulmonary arteries approximately 70 to 90 days post-infection and reach sexual maturity at 6 to 7 months [4, 2]. Adult worms can survive for 5 to 7 years within the canine host [4].

How Do You Get Heartworm in Dogs

Transmission occurs exclusively through the bite of a mosquito carrying infective L3 larvae [5, 6]. The question "how do you get heartworm in dogs" is answered by the vector-borne nature of the parasite: there is no direct dog-to-dog transmission [1]. The likelihood of infection depends on the density of infected mosquitoes, the duration of exposure, and the absence of chemoprophylaxis [9, 10]. In endemic regions, transmission risk is highest during warm months when mosquito activity and EIP completion coincide [11, 7]. Studies have demonstrated that risk factors for antigen positivity include location in a high-prevalence zone (e.g., northern Queensland, Australia) [9], adult or geriatric age [10], male sex [10], intact reproductive status [10], and diagnosis during the dry season [10]. Imported cases, so-called "baggage canine heartworm," can occur when infected mosquitoes are transported in luggage from endemic to non-endemic areas [12]. Autochthonous infections have been documented in previously non-endemic regions such as Estonia, indicating ongoing northward expansion of D. immitis in Europe [13].

Epidemiology and Geographic Distribution

Dirofilaria immitis has a cosmopolitan distribution, with endemic foci on every continent except Antarctica [14, 7]. Prevalence varies widely: a necropsy study of stray dogs in Grenada reported 27.5% positivity [15], while shelter dogs in Queensland, Australia, showed 9.6% positivity by combined antigen, microfilaria, and PCR testing [9]. In temperate climates, transmission historically was sporadic, but warming trends have expanded the suitable transmission window [5, 13, 7]. A survey of European veterinary practitioners indicated that 10% of respondents from non-endemic regions reported an increasing number of cases, and 44% considered it likely that heartworm would become endemic in their area [14]. In Ukraine, dirofilariasis has transitioned from a sporadic disease to a widespread pathology, attributed to climate change and animal movement [5]. The development of a public dashboard using HDU-based modeling now allows real-time assessment of transmission risk across Australia [8].

Pathogenesis and Clinical Signs

The primary pathologic lesions are caused by the presence of adult worms in the pulmonary arteries [3, 1]. Physical contact between the parasite and the vascular endothelium triggers proliferative endarteritis, villous intimal hyperplasia, and thrombosis [16, 17]. The severity of disease is correlated with worm burden, duration of infection, and host immune response [3]. The bacterial endosymbiont Wolbachia pipientis plays a critical role in driving inflammation; its release upon worm death exacerbates pulmonary thromboembolism and acute respiratory distress [18, 2]. Chronic infection leads to precapillary pulmonary hypertension (PH) due to irreversible structural remodeling of the arterial wall [16, 17]. Clinical signs include cough, exercise intolerance, dyspnea, syncope, and signs of right-sided congestive heart failure (ascites, jugular distension) [1]. In a cohort of naturally infected dogs, PH (defined by right pulmonary artery distensibility index < 29.5%) was present in 47.4% of cases [17]. Biomarkers such as cardiac troponin I (cTnI) are elevated in both symptomatic and asymptomatic infections, while N-terminal pro B-type natriuretic peptide (NT-proBNP) is increased only in dogs with clinical signs, reflecting myocardial stretch [19]. Tumor necrosis factor alpha dynamics have also been investigated as inflammatory markers during diagnosis and treatment [20].

Diagnostic Approaches

Diagnosis relies on detection of circulating adult female worm antigens, identification of microfilariae, and imaging [9, 3, 6]. The reference method for antigen detection is a microwell-based enzyme-linked immunosorbent assay (ELISA) targeting glycoproteins shed by adult D. immitis [9]. Heat treatment of plasma prior to testing can increase optical density in antigen-positive samples, though in one study it did not alter the qualitative result (Cohen's kappa = 0.98) [9]. Modified Knott's test remains the standard for microfilarial detection and allows morphologic differentiation from Acanthocheilonema reconditum [9, 12]. Real-time PCR targeting D. immitis DNA provides species confirmation and is particularly useful when antigen tests are positive but microfilariae are absent (occult infections) [12, 6].

Imaging techniques include thoracic radiography and echocardiography [21, 16, 17, 11]. Radiographic signs of heartworm disease include enlargement of the caudal lobar pulmonary arteries, increased sternal contact of the cardiac silhouette, reversed-D heart shape, and loss of pulmonary vessel margination [21, 11]. Objective radiographic measurements such as modified vertebral heart size (VHS) and cardiac sphericity index are feasible and repeatable [21]. Echocardiography enables direct visualization of adult worms as parallel echogenic lines ("tram tracks") within the pulmonary arteries, evaluation of right ventricular function, and estimation of pulmonary hypertension [12, 16, 17]. The pulmonary vein to pulmonary artery ratio (PV:PA ratio) measured by M-mode or two-dimensional echocardiography has high diagnostic accuracy for moderate-to-severe PH (cut-off ≤ 0.845, sensitivity 97%, specificity 94%) [16]. Tissue Doppler imaging further aids PH assessment, with indices such as E':A' and right myocardial performance index demonstrating excellent sensitivity and specificity [17].

A summary of diagnostic methods is provided in Table 1.

Table 1. Diagnostic Methods for Canine Heartworm Disease

Treatment Protocols

The adulticide of choice is melarsomine dihydrochloride, an arsenical compound administered via deep intramuscular injection into the paralumbar muscles [22, 18]. The recommended protocol involves two doses 24 hours apart (2.5 mg/kg each) followed by a third dose 30 days later [23, 24]. Because melarsomine is highly irritative, precise injection technique is critical; ultrasonographic guidance has been proposed to measure muscle depth and monitor drug distribution [22]. Exercise restriction is mandatory throughout treatment to reduce the risk of thromboembolic complications [23].

In cases where arsenical therapy is contraindicated or declined, alternative "slow-kill" approaches using macrocyclic lactones (MLs) combined with doxycycline targeting Wolbachia have been employed [18, 25, 26]. Doxycycline (10 mg/kg twice daily for 28 days) depletes Wolbachia, rendering adult worms more susceptible to MLs and reducing microfilaremia [18, 26]. Minocycline may be considered as a substitute, with pharmacokinetic-pharmacodynamic analyses suggesting a dose of 3.75 to 5 mg/kg twice daily to achieve anti-Wolbachia efficacy [26]. The combination of ivermectin or moxidectin with doxycycline has shown adulticidal effects, although efficacy is lower than with melarsomine [18]. Notably, survey data indicate that 74% of veterinarians surveyed endorsed long-term ML monotherapy (slow-kill) when clients declined melarsomine, despite guideline recommendations against it [23]. Concerns about ML resistance have emerged, with reports of reduced microfilarial suppression after moxidectin treatment in Australia; however, genotyping of single nucleotide polymorphisms associated with resistance in the USA did not correlate with the observed phenotype [27].

A treatment decision tree is presented in Figure 1.

graph TD
    A[Confirmed D. immitis infection], > B{Clinical signs?}
    B, >|Yes| C[Evaluate severity of PH and right heart failure]
    B, >|No| D[Asymptomatic]
    C, > E{Melarsomine indicated?}
    E, >|Yes| F[Three-dose protocol + exercise restriction + doxycycline 28d]
    E, >|No (owner declines / contraindicated)| G[Slow-kill: monthly ML + doxycycline/minocycline 28d]
    D, > H{Melarsomine indicated?}
    H, >|Yes| I[Three-dose protocol + doxycycline]
    H, >|No| J[Slow-kill as above]
    F, > K[Post-treatment antigen test at 6-12 months]
    G, > K
    I, > K
    J, > K
    K, > L{Antigen negative?}
    L, >|Yes| M[Cure confirmed; continue prevention]
    L, >|No| N[Consider retreatment or alternative therapy]

Post-treatment monitoring involves repeating antigen testing approximately 6 to 12 months after the final melarsomine injection to confirm clearance [12, 24]. Cardiac biomarkers such as cTnI may aid in monitoring myocardial injury during treatment [19]. Radiographic parameters, particularly main pulmonary artery enlargement and loss of vessel margination, can improve after successful therapy [21].

Prevention

Prevention relies on monthly administration of macrocyclic lactones (ivermectin, milbemycin oxime, moxidectin, selamectin) that kill tissue-stage larvae (L3 and L4) before they reach the pulmonary arteries [18, 28]. Integrated parasite control using combination products that also target fleas (e.g., moxidectin + imidacloprid) offers additional compliance benefits [27]. The American Heartworm Society recommends year-round prevention in endemic areas and seasonal prevention in regions with defined transmission windows [28]. The "Transmission Tracker – Dirofilaria" dashboard provides real-time temperature-based risk assessment to guide such decisions [8]. Adherence to prevention is the single most important factor; studies have repeatedly shown that lapses in prophylaxis are the predominant cause of infection [25, 29].

References

[1] Ye H. Heartworm disease in canines. Theor Nat Sci. 2024.

[2] McHaffie J. Dirofilaria immitis and Wolbachia pipientis: a thorough investigation of the symbiosis responsible for canine heartworm disease. Parasitol Res. 2012.

[3] Sinanis T, Koutinas C, Diakou A, et al. Canine heartworm disease (dirofilariosis): pathogenesis and diagnosis of a multidimensional disease. J. 2017.

[4] Schwartz A. Canine Heartworm Disease The Current Knowledge. J. 2016.

[5] Bovsunovska K, Chepilko K. Heartworm disease in Ukraine: a rapid transition from a sporadic disease to a widespread pathology. Clinical case. Ukr Sci Med Youth J. 2025.

[6] Ogawa G, Cruz EN, Cunha PNA, et al. Canine heartworm disease in Porto Velho: first record, distribution map and occurrence of positive mosquitoes. Rev Bras Parasitol Vet. 2013.

[7] Atkinson PJ, Stevenson M, O'Handley R, et al. Temperature-bounded development of Dirofilaria immitis larvae restricts the geographical distribution and seasonality of its transmission: case study and decision support system for canine heartworm management in Australia. Int J Parasitol. 2024.

[8] Atkinson PJ, Stevenson M, O'Handley R, et al. 'Transmission Tracker – Dirofilaria'– a public dashboard to assess in real‐time the temperature‐bounded transmissibility of canine heartworm across Australia. Aust Vet J. 2024.

[9] Panetta JL, Calvani N, Orr B, et al. Multiple diagnostic tests demonstrate an increased risk of canine heartworm disease in northern Queensland, Australia. Parasit Vectors. 2021.

[10] Kabuusu R, Stroup D, Pinckney R, et al. An analysis of time trends for canine heartworm disease in Grenada and its associated risk factors based on veterinary clinical pathology laboratory data base records between 2003 and 2015. Prev Vet Med. 2020.

[11] Lima NC, Paula MAS, Mattos RB, et al. Radiographic findings in dogs from an endemic area for heartworm disease in the state of Rio de Janeiro. Braz J Vet Med. 2025.

[12] McKeever B, Podadera J, Beijerink N, et al. Suspect 'baggage canine heartworm' case: canine heartworm disease in a dog from Sydney, New South Wales. Aust Vet J. 2021.

[13] Mõttus M, Mõtsküla P, Jokelainen P. Heartworm disease in domestic dogs in Estonia: indication of local circulation of the zoonotic parasite Dirofilaria immitis farther north than previously reported. Parasit Vectors. 2024.

[14] Genchi C, Bowman D, Drake J. Canine heartworm disease (Dirofilaria immitis) in Western Europe: survey of veterinary awareness and perceptions. Parasit Vectors. 2014.

[15] Brown MC, Chikweto A, Tiwari K, et al. Prevalence of Canine Heartworm Disease in Stray Dogs of Grenada, West Indies. J. 2017.

[16] Matos J, Caro-Vadillo A, Falcón-Cordón Y, et al. Echocardiographic Assessment of the Pulmonary Vein to Pulmonary Artery Ratio in Canine Heartworm Disease. Animals. 2023.

[17] Matos J, García-Rodríguez SN, Costa-Rodríguez N, et al. Usefulness of Tissue Doppler Imaging for the Evaluation of Pulmonary Hypertension in Canine Heartworm Disease. Animals. 2023.

[18] Kramer L, Crosara S, Gnudi G, et al. Wolbachia, doxycycline and macrocyclic lactones: New prospects in the treatment of canine heartworm disease. Vet Parasitol. 2018.

[19] Asawakarn S, Tachampa K, Taweethavonsawat P. Cardiac Biomarkers for Monitoring Canine Heartworm Disease: A Comparative Study of N-Terminal Pro B Type Natriuretic Peptide and Cardiac Troponin I Levels. Thai J Vet Med. 2024.

[20] Spasojević Kosić L, Vračar V, Kozoderović G, et al. Detection and dynamics of tumor necrosis factor alpha in the diagnosis and treatment of canine heartworm disease. Veterinaria Italiana. 2024.

[21] Kosić L. Feasibility and findings of different radiographic methods in diagnosing canine heartworm disease. Open Vet J. 2026.

[22] Vörös K, Becker Z, Dudás Györki Z, et al. Ultrasonography of the paralumbar muscles as a new aid during melarsomine treatment in canine heartworm disease. Description and illustration of the method - A preliminary study. Acta Vet Hung. 2022.

[23] Dixon-Jimenez AC, Coleman A, Rapoport G, et al. Approaches to Canine Heartworm Disease Treatment Among Alumni of a Single College of Veterinary Medicine. J Am Anim Hosp Assoc. 2018.

[24] Tomohiro I, Jun S. Clinical Experience of the Treatment by Oral Administration of Doxycycline and Ivermectin Combined with a Single Injection of Melarsomine for Canine Heartworm Disease. J. 2017.

[25] Ku T. Investigating management choices for canine heartworm disease in northern Mississippi. Parasit Vectors. 2017.

[26] Papich M. Considerations for using minocycline vs doxycycline for treatment of canine heartworm disease. Parasit Vectors. 2017.

[27] Power RI, Šlapeta J. Delayed canine heartworm (Dirofilaria immitis) microfilarial reduction following AdvocateTM for Dogs (imidacloprid, moxidectin) treatment. Vet J. 2024. *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[28] Sinanis T, Σινανης ΘΝ, Koutinas C, et al. Τreatment and prevention of canine heartworm disease (dirofilariosis): what is new? J. 2017.

[29] Ku T. Investigating veterinary management choices for canine heartworm disease (Dirofilaria immitis) in northern Mississippi. J. 2017.

[30] Gabrielli S, Mendoza-Roldan J, Napoli E, et al. Human exposure to Dirofilaria immitis following a canine heartworm disease elimination program in Linosa Island (Sicily, Italy). Acta Tropica. 2025.

[31] Chambers C. Variation of drug timing and its effect on "susceptibility gap" larvae in canine heartworm disease treatment. J. 2021.

[32] Monobe MM, Silva R, Melanchauski MS, et al. Canine heartworm disease in a Brazilian non-endemic area. J. 2016.

[33] Savadelis MD. Focus on Canine Heartworm Disease. J. 2017.

[34] Montoya-Alonso JA, Balmori-de la Puente A, Costa-Rodríguez N, et al. A One Health Perspective on Heartworm Disease: Allergy Risk in Owners of Infected Dogs in Gran Canaria (Spain). Animals. 2025.

[35] Sharma SK, Rathore G, Head P, et al. Clinico-therapeutic studies on canine heartworm disease. J.